Male%20infertility Patient Education

Patient Education

Lifestyle Modification

Alcohol & Smoking

Alcohol consumption should be limited to 3-4 units/day
Cessation of smoking should be encouraged
Excessive alcohol intake & smoking may affect sperm quality

Body Weight

Men w/ body mass index (BMI) of >30 kg/m² are at greater risk of being infertile
Obesity may lead to androgen to estrogen conversion, decreased SHBG levels, secondary to insulin resistance
Weight loss should be encouraged especially for patients w/ alterations in the hypothalamic-pituitary-testicular axis & impaired scrotal thermoregulation

Caffeine Intake

There are inconsistent evidences concerning the effect of consumption of caffeinated beverages on fertility

Control of Body Temperature

Tight underwear are associated w/ elevated scrotal temperature & reduced semen quality
Wearing boxer shorts & loose underwear are more advisable
Avoid going to hot baths & saunas w/c can increase scrotal temperature

Discontinue Offending Medications & Exposures

Many common medications & occupational hazards may affect male sexual function
- Eg antidepressants, antipsychotics, anti-arrhythmics, many antihypertensives, anti-androgens & steroids

Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer

Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas.